Results 71 to 80 of about 18,742 (250)

Weight Gain in Type 2 Diabetes Mellitus Patients Receiving Sulfonylurea Medications at a Tertiary Hospital in Surabaya, Indonesia

Current Internal Medicine Research and Practice Surabaya Journal
Introduction: Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by persistent hyperglycemia. The prevalence of diabetes in Indonesia is 1.5%, although East Java recorded a 2.1% rate in 2013.
Ghagat Dresta Putra Respati, Jongky Hendro Prajitno, Rosy Setiawati, Rio Wironegoro   +3 more
doaj   +1 more source

Glucagon‐Like Peptide‐1 Receptor Agonists and Incident Major Adverse Liver Outcomes in People With Type 2 Diabetes and Metabolic Dysfunction‐Associated Steatotic Liver Disease

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Treatment options for metabolic dysfunction‐associated steatotic liver disease (MASLD) are limited. While glucagon‐like peptide‐1 receptor agonists (GLP‐1 RA) and sodium‐glucose cotransporter‐2 (SGLT‐2) inhibitors improve cardiovascular outcomes, comparative effectiveness on liver‐related outcomes remains unclear.
Gregor A. Maier, Ramon A. Hofmann, Michael Roden, Wolfgang Rathmann, Oliver Kuss   +4 more
wiley   +1 more source

A Four‐Week Treatment With Dapagliflozin Is Associated With a Reduction in Insulin‐Stimulated Renal Cortical Glucose Uptake: A Post Hoc Analysis From a Pilot Study

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Introduction and Objective Treatment with sodium‐glucose cotransporter‐2 inhibitors (SGLT‐2i) reduces the risk of both cardiovascular and renal outcomes in type 2 diabetes (T2D). The specific mechanism by which this happens has not yet been clarified.
Shawn Gugliandolo, Cassandra Morciano, Andrea Guarneri, Gian Pio Sorice, Marta Giaccari, Luigi Cappannoli, Umberto Capece, Amelia Splendore, Adriana Avolio, Lorenzo Diego Greco, Patricia Iozzo, Rossana Moroni, Alfredo Pontecorvi, Maria Lucia Calcagni, Francesco Burzotta, Domenico D'Amario, Filippo Crea, Lucia Leccisotti, Francesca Cinti   +18 more
wiley   +1 more source

An Overview of the Pharmacogenetics of Sulfonylurea in Type 2 Diabetes Mellitus [PDF]

Journal of Advanced Pharmacy Research
Background and Objective: Diabetes mellitus (DM) is a prevalent disease, with its prevalence increasing over the past few decades, posing a significant public health challenge.
Bayan Aljabali, Dima Joujeh
doaj   +1 more source

Efficacy and Safety of Intensifying Once‐Weekly Insulin Icodec Treatment With Once‐Weekly Semaglutide in Adults With Type 2 Diabetes: A Single‐Arm, Open‐Label, Treat‐to‐Target, Phase 3b Trial (ONWARDS 8)

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To investigate the efficacy and safety of intensifying once‐weekly insulin icodec (icodec) with once‐weekly semaglutide in adults with type 2 diabetes (T2D). Materials and Methods ONWARDS 8 was a single‐arm, open‐label, treat‐to‐target, Phase 3b trial comprising a 26‐week icodec run‐in period and a 26‐week semaglutide intensification ...
Krzysztof Strojek, Andreas Liebl, Neha Narendra Mumbaikar, Stinne Byrholdt Søgaard, Sara Kehlet Watt, Athena Philis‐Tsimikas   +5 more
wiley   +1 more source

Potential Mediators of Efpeglenatide's Cardiovascular Benefit: An Exploratory Analysis of the AMPLITUDE‐O Trial

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims In the AMPLITUDE O trial, efpeglenatide reduced major cardiovascular events by 27% in 4076 individuals with Type 2 diabetes and established cardiovascular or kidney disease compared to placebo during a median follow‐up of 1.81 years. This exploratory mediation analysis evaluates the degree to which changes in measured clinical variables ...
Daniel Raaschou‐Oddershede, Christine R. Schwarz, Tanya Kovalova, Kelley R. Branch, Stefano Del Prato, Carolyn S. P. Lam, Renato D. Lopes, Richard Pratley, Julio Rosenstock, Naveed Sattar, Hertzel C. Gerstein   +10 more
wiley   +1 more source

Semaglutide Injection Once‐Weekly for Weight Management in Adults: Results From A Randomized Phase III, Active‐Controlled Study

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aim To evaluate and compare the efficacy, safety, and immunogenicity of a synthetic semaglutide injection (Test semaglutide) with Wegovy (Reference semaglutide) injection for weight management. Materials and Methods This randomized, Phase III, non‐inferiority study included adults with obesity or overweight with or without comorbidities from ...
Unnikrishnan Ambika Gopalakrishnan, Ameya Joshi, Harish Kumar, Richa Giri, Sanjiv Maheshwari, Valluri Satya Prasad, Jitendra Shukla, Rekha M. Chowdaiah, Nutan Kumar Agrawal, Yogesh Rasal, Banshidhar Sahoo, Shweta Bhandari, Ambanna Gowda, Uday Phadke, Pravin Supe, Niranjan Pathak, Ambrish Chandrappa, Ashutosh Sonawane, Yash Bahulikar, Amit Bhaskar, Arunkumar Radhakrishnan, Priyanka Yadav, Sucheta Pandit, Supriya Sonowal, Dipak Patil, Pravin Ghadge, Suyog Mehta   +26 more
wiley   +1 more source

Durability and Safety of Imeglimin as an Add‐On to DPP‐4 Inhibitors in Japanese Type 2 Diabetes: The 104‐Week FAMILIAR Trial

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To evaluate the long‐term efficacy and safety of imeglimin added to dipeptidyl peptidase‐4 (DPP‐4) inhibitors in Japanese patients with type 2 diabetes, focusing on glycemic durability and safety in elderly patients over 104 weeks. Materials and Methods This multicenter, randomized, placebo‐controlled trial comprised a 24‐week double ...
Masashi Shimoda, Takeshi Osonoi, Masahiro Iwamoto, Hideaki Kaneto, Kohei Kaku   +4 more
wiley   +1 more source

Effectiveness of Telehealth Low‐Carbohydrate Intervention in Preventing Chronic Kidney Disease: A Real‐World, Retrospective, Matched Cohort Study

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Background Lifestyle interventions targeting metabolic health may influence chronic kidney disease (CKD) risk, particularly among adults with type 2 diabetes and obesity. We evaluated real‐world associations between a telehealth‐delivered, individualized nutrition therapy program (VINT) and CKD incidence and progression compared with usual ...
Shaminie J. Athinarayanan, Petter Bjornstad, Priya V. Shanmugam, Thomas Weimbs, Adam J. Wolfberg, Jeff S. Volek, Jonathan Himmelfarb, Richard J. Johnson   +7 more
wiley   +1 more source

Association Between Time in Range and Advanced Cardiovascular‐Kidney‐Metabolic Syndrome in Older Adults With Type 2 Diabetes

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Cardiovascular, kidney and metabolic diseases are pathophysiologically interrelated and are conceptualised within the cardiovascular‐kidney‐metabolic (CKM) syndrome framework. However, evidence linking continuous glucose monitoring (CGM) to CKM syndrome remains limited.
Hang Su, Jiaying Ni, Jinghao Cai, Wei Zhu, Yufei Wang, Jian Zhou, Jingyi Lu, Xiaojing Ma   +7 more
wiley   +1 more source